FDA Expands Approval of GSK's RSV Vaccine to Adults Aged 50-59

The vaccine, previously approved for those over 60, now covers younger high-risk adults with chronic conditions.

GSK's Arexvy is the first RSV vaccine approved for adults aged 50-59.
The FDA's decision follows trials showing strong immune responses in this age group.
Around 13 million Americans in their 50s are at increased risk of severe RSV due to chronic health issues.
The CDC's advisory panel will vote on recommendations for the vaccine later this month.
GSK is also seeking regulatory approval in Europe, Japan, and other regions.